PortalPublikationenEvaluation of Integrated HPV DNA as Individualized Biomarker...

Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance

Standard

Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance. / Hoyer, Heike; Mehlhorn, Grit; Scheungraber, Cornelia; Hagemann, Ingke; Hirchenhain, Christine; Woelber, Linn; Stolte, Claudia; Hampl, Monika; Scherbring, Sarah; Denecke, Agnieszka; Bartels, Janina; Ebert, Andreas D; Meneder, Sabina; Petzold, Annett; Heller, Tabitha; Heidtke, Karsten R; Schwarz, Elisabeth; Stübs, Frederik; Schütze, Stefanie; Stange, Eva-Lena; Jaeger, Anna; Martignoni, Franca; Dellmann, Ansgar; Rody, Achim; Hillemanns, Peter; Fehm, Tanja; Petry, Karl-Ulrich; Böhmer, Gerd; Schmalfeldt, Barbara; Wimberger, Pauline; Beckmann, Matthias W; Runnebaum, Ingo B; Dürst, Matthias.

in: CANCERS, Jahrgang 13, Nr. 13, 3309, 01.07.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hoyer, H, Mehlhorn, G, Scheungraber, C, Hagemann, I, Hirchenhain, C, Woelber, L, Stolte, C, Hampl, M, Scherbring, S, Denecke, A, Bartels, J, Ebert, AD, Meneder, S, Petzold, A, Heller, T, Heidtke, KR, Schwarz, E, Stübs, F, Schütze, S, Stange, E-L, Jaeger, A, Martignoni, F, Dellmann, A, Rody, A, Hillemanns, P, Fehm, T, Petry, K-U, Böhmer, G, Schmalfeldt, B, Wimberger, P, Beckmann, MW, Runnebaum, IB & Dürst, M 2021, 'Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance', CANCERS, Jg. 13, Nr. 13, 3309. https://doi.org/10.3390/cancers13133309

APA

Hoyer, H., Mehlhorn, G., Scheungraber, C., Hagemann, I., Hirchenhain, C., Woelber, L., Stolte, C., Hampl, M., Scherbring, S., Denecke, A., Bartels, J., Ebert, A. D., Meneder, S., Petzold, A., Heller, T., Heidtke, K. R., Schwarz, E., Stübs, F., Schütze, S., ... Dürst, M. (2021). Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance. CANCERS, 13(13), [3309]. https://doi.org/10.3390/cancers13133309

Vancouver

Hoyer H, Mehlhorn G, Scheungraber C, Hagemann I, Hirchenhain C, Woelber L et al. Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance. CANCERS. 2021 Jul 1;13(13). 3309. https://doi.org/10.3390/cancers13133309

Bibtex

@article{18b01bc8696a48df84db87ee82334ccd,
title = "Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance",
abstract = "PURPOSE: Post-treatment follow-up in women with cervical pre-cancers (CIN3) is mandatory due to relapse in up to 10% of patients. Standard follow-up based on hrHPV-DNA/cytology co-testing has high sensitivity but limited specificity. The aim of our prospective, multicenter, observational study was to test the hypothesis that an individualized viral-cellular-junction test (vcj-PCR) combined with cytology has a lower false positive rate for the prediction of recurrence compared to standard co-testing.METHODS: Pre-surgical cervical swabs served for the identification of HPV16/18 DNA integration sites by next-generation-sequencing (NGS). Samples taken at 6, 12 and 24 months post-surgery were evaluated by cytology, hrHPV-DNA and the patients' individual HPV-integration sites (vcj-PCR on the basis of NGS).RESULTS: Integration sites were detected in 48 of 445 patients (10.8%), 39 of them had valid follow-up data. The false positive rate was 18.2% (95% CI 8.6-34.4%) for standard hrHPV/cytology at six months compared to 12.1% (95% CI 4.8-27.3%) for vcj-PCR/cytology, respectively (McNemar p = 0.50). Six patients developed recurrences (1 CIN2, 5 CIN3) during follow-up. Standard co-testing detected all, whereas vcj-PCR/cytology detected only five patients with recurrences. Data of 269 patients without evidence of HPV16/18 integration were subject to post-hoc analyses. Standard co-testing revealed a false positive rate of 15.7% (95% CI 11.7-20.7%) and predicted ten of fourteen recurrences at six months.CONCLUSIONS: Although highly specific on its own vcj-PCR could not detect all recurrent CIN2/3. Possible reasons for this unexpected result may be multifocal lesions, intratumoral heterogeneity with respect to HPV integration and/or incident CIN.",
author = "Heike Hoyer and Grit Mehlhorn and Cornelia Scheungraber and Ingke Hagemann and Christine Hirchenhain and Linn Woelber and Claudia Stolte and Monika Hampl and Sarah Scherbring and Agnieszka Denecke and Janina Bartels and Ebert, {Andreas D} and Sabina Meneder and Annett Petzold and Tabitha Heller and Heidtke, {Karsten R} and Elisabeth Schwarz and Frederik St{\"u}bs and Stefanie Sch{\"u}tze and Eva-Lena Stange and Anna Jaeger and Franca Martignoni and Ansgar Dellmann and Achim Rody and Peter Hillemanns and Tanja Fehm and Karl-Ulrich Petry and Gerd B{\"o}hmer and Barbara Schmalfeldt and Pauline Wimberger and Beckmann, {Matthias W} and Runnebaum, {Ingo B} and Matthias D{\"u}rst",
year = "2021",
month = jul,
day = "1",
doi = "10.3390/cancers13133309",
language = "English",
volume = "13",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "13",

}

RIS

TY - JOUR

T1 - Evaluation of Integrated HPV DNA as Individualized Biomarkers for the Detection of Recurrent CIN2/3 during Post-Treatment Surveillance

AU - Hoyer, Heike

AU - Mehlhorn, Grit

AU - Scheungraber, Cornelia

AU - Hagemann, Ingke

AU - Hirchenhain, Christine

AU - Woelber, Linn

AU - Stolte, Claudia

AU - Hampl, Monika

AU - Scherbring, Sarah

AU - Denecke, Agnieszka

AU - Bartels, Janina

AU - Ebert, Andreas D

AU - Meneder, Sabina

AU - Petzold, Annett

AU - Heller, Tabitha

AU - Heidtke, Karsten R

AU - Schwarz, Elisabeth

AU - Stübs, Frederik

AU - Schütze, Stefanie

AU - Stange, Eva-Lena

AU - Jaeger, Anna

AU - Martignoni, Franca

AU - Dellmann, Ansgar

AU - Rody, Achim

AU - Hillemanns, Peter

AU - Fehm, Tanja

AU - Petry, Karl-Ulrich

AU - Böhmer, Gerd

AU - Schmalfeldt, Barbara

AU - Wimberger, Pauline

AU - Beckmann, Matthias W

AU - Runnebaum, Ingo B

AU - Dürst, Matthias

PY - 2021/7/1

Y1 - 2021/7/1

N2 - PURPOSE: Post-treatment follow-up in women with cervical pre-cancers (CIN3) is mandatory due to relapse in up to 10% of patients. Standard follow-up based on hrHPV-DNA/cytology co-testing has high sensitivity but limited specificity. The aim of our prospective, multicenter, observational study was to test the hypothesis that an individualized viral-cellular-junction test (vcj-PCR) combined with cytology has a lower false positive rate for the prediction of recurrence compared to standard co-testing.METHODS: Pre-surgical cervical swabs served for the identification of HPV16/18 DNA integration sites by next-generation-sequencing (NGS). Samples taken at 6, 12 and 24 months post-surgery were evaluated by cytology, hrHPV-DNA and the patients' individual HPV-integration sites (vcj-PCR on the basis of NGS).RESULTS: Integration sites were detected in 48 of 445 patients (10.8%), 39 of them had valid follow-up data. The false positive rate was 18.2% (95% CI 8.6-34.4%) for standard hrHPV/cytology at six months compared to 12.1% (95% CI 4.8-27.3%) for vcj-PCR/cytology, respectively (McNemar p = 0.50). Six patients developed recurrences (1 CIN2, 5 CIN3) during follow-up. Standard co-testing detected all, whereas vcj-PCR/cytology detected only five patients with recurrences. Data of 269 patients without evidence of HPV16/18 integration were subject to post-hoc analyses. Standard co-testing revealed a false positive rate of 15.7% (95% CI 11.7-20.7%) and predicted ten of fourteen recurrences at six months.CONCLUSIONS: Although highly specific on its own vcj-PCR could not detect all recurrent CIN2/3. Possible reasons for this unexpected result may be multifocal lesions, intratumoral heterogeneity with respect to HPV integration and/or incident CIN.

AB - PURPOSE: Post-treatment follow-up in women with cervical pre-cancers (CIN3) is mandatory due to relapse in up to 10% of patients. Standard follow-up based on hrHPV-DNA/cytology co-testing has high sensitivity but limited specificity. The aim of our prospective, multicenter, observational study was to test the hypothesis that an individualized viral-cellular-junction test (vcj-PCR) combined with cytology has a lower false positive rate for the prediction of recurrence compared to standard co-testing.METHODS: Pre-surgical cervical swabs served for the identification of HPV16/18 DNA integration sites by next-generation-sequencing (NGS). Samples taken at 6, 12 and 24 months post-surgery were evaluated by cytology, hrHPV-DNA and the patients' individual HPV-integration sites (vcj-PCR on the basis of NGS).RESULTS: Integration sites were detected in 48 of 445 patients (10.8%), 39 of them had valid follow-up data. The false positive rate was 18.2% (95% CI 8.6-34.4%) for standard hrHPV/cytology at six months compared to 12.1% (95% CI 4.8-27.3%) for vcj-PCR/cytology, respectively (McNemar p = 0.50). Six patients developed recurrences (1 CIN2, 5 CIN3) during follow-up. Standard co-testing detected all, whereas vcj-PCR/cytology detected only five patients with recurrences. Data of 269 patients without evidence of HPV16/18 integration were subject to post-hoc analyses. Standard co-testing revealed a false positive rate of 15.7% (95% CI 11.7-20.7%) and predicted ten of fourteen recurrences at six months.CONCLUSIONS: Although highly specific on its own vcj-PCR could not detect all recurrent CIN2/3. Possible reasons for this unexpected result may be multifocal lesions, intratumoral heterogeneity with respect to HPV integration and/or incident CIN.

U2 - 10.3390/cancers13133309

DO - 10.3390/cancers13133309

M3 - SCORING: Journal article

C2 - 34282754

VL - 13

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 13

M1 - 3309

ER -